VO659

PreclinicalSmall molecule

VVico Therapeutics B. V.

VO659 is one of 2 small molecule programs targeting Spinocerebellar Ataxia Type 1. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinocerebellar Ataxia Type 1Recruiting

Spinocerebellar Ataxia Type 1Preclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Spinocerebellar Ataxia Type 1

#DrugCompanyPhaseTrials

Lithobid

SSolvay Pharmaceuticals

Approved

—2

VO659

VVico Therapeutics B. V.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Spinocerebellar Ataxia Type 1

NCT05822908

Clinical

Trials by Indication[1]

Spinocerebellar Ataxia Type 11 trial

A Phase 1/2a, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered VO659 in Participants With Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease

Recruiting·VVico Therapeutics B. V.·Preclinical·NCT05822908·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VO659. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VO659 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VO659. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vico Therapeutics B. V. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVico Therapeutics B. V.

VO659

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Spinocerebellar Ataxia Type 11 trial

References

Drug Info

Quick Facts

Related News